Insurers, concerned about the spiraling cost of specialty drugs, are pushing to link payment for these pharmaceuticals to their performance.

The Boston Globe reports that “biopharma companies are bracing for payment changes, fearful they could cut into profits or dampen the enthusiasm of investors. But they are also hoping to capitalize on the so-called pay for performance trend with a new generation of targeted therapies that can effectively treat a higher share of patients with specific genetic mutations.”